# US 9,751,949 B2 · Method of inhibiting adipogenesis with an IL-20 antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,751,949 B2
- Document ID: US9751949B2
- Status: Granted
- Kind: B2
- Application number: 14/306,650
- Filed: 2014-06-17
- Published: 2014-12-18
- Granted: 2017-09-05
- Earliest claimed: 2013-06-17
- Assignees: National Cheng Kung University
- Applicants: National Cheng Kung University
- Inventors: Ming-Shi Chang; Yu-Hsiang Hsu
- Web page: https://patentgrep.com/patent/US9751949B2

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 3/04: Anorexiants; Antiobesity agents
- C07K 16/244: {Interleukins [IL]}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Alleviating obesity in a subject (e.g., a human subject) having, obesity using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.

## Claims

### Claim 1

A method for inhibiting adipogenesis in a subject, comprising administering to a subject in need thereof an effective amount of an IL-20 antagonist, wherein the IL-20 antagonist is an antibody that binds IL-20.

### Claim 2 (depends on 1)

The method of claim 1, wherein the anti-IL-20 antibody is monoclonal antibody mAb7E, an antigen-binding fragment thereof, or a functional variant thereof, and wherein the functional variant comprises the same complementary determining regions (CDRs) as mAb7E.

### Claim 3 (depends on 2)

The method of claim 2, wherein the functional variant is a humanized antibody of mAb7E.

### Claim 4 (depends on 3)

The method of claim 3, wherein the humanized antibody comprises a heavy chain variable region (VH), which comprises the amino acid sequence of SEQ ID NO:8, and a light chain variable region (VL), which comprises the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:13.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antibody is a full-length antibody or an antigen-binding fragment thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the antibody is a human antibody, a humanized antibody, a chimeric antibody, or a single-chain antibody.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is a human patient having obesity induced by diet.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject is a human patient having obesity induced by a genetic factor.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject has obesity.

### Claim 10 (depends on 9)

The method of claim 9, wherein the subject is a human obesity patient.